ArticleVeterinary research2025
Isolation, characterization, and application of the novel polyvalent bacteriophage vB_EcoM_XAM237 against pathogenic Escherichia coli.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Phenotypic and Genomic Characterization of Novel Straboviridae Bacteriophages Targeting Multidrug-ResistantMicroorganisms · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation and characterization of a lytic bacteriophage against Staphylococcus aureus.BMC veterinary research · 2026Article
- Broth Optical Density-Based Assessment for Phage Therapy: Turbidity Reduction, Antibacterial Virulence, and Time-Kill.Viruses · 2026Review
- Synergistic therapy of Chinese herbal medicine and gut microbiota modulation for post-stroke cognitive recovery: focus on microbial metabolite and immunoinflammation.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
A novel polyvalent broad-spectrum phage, vB_EcoM_XAM237 (XAM237), was isolated from pig farm sewage. It can simultaneously lyse multiple strains of pathogenic Escherichia coli (E. coli), demonstrating a broad host range. When the enteropathogenic E. coli (EPEC) strain E711 was used as the host bacterium, the phage XAM237 exhibited a short latent period, high stability at different temperatures and pH values and good tolerance to chloroform. Moreover, phage XAM237 can efficiently adsorb and lyse host bacteria in vitro. Whole-genome sequencing revealed that XAM237 is a double-stranded DNA (dsDNA) phage consisting of 170 541 bp with a G + C content of 35%. Phylogenetic analysis confirmed that XAM237 belongs to the family Straboviridae, genus Tequatrovirus. In addition, the genome of XAM237 did not contain genes related to lysogenicity, virulence or antimicrobial resistance. The effects of phage XAM237 in treating EPEC infections in vivo were evaluated in a mouse model. Phage XAM237 was able to reduce the number of colonized aEPEC strain E711 in the small intestine, liver, spleen, and kidney. This study suggested that phage XAM237 may be a promising candidate biologic agent for controlling pathogenic E. coli infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.